Study wrapper · #973
Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
Gu YM, Yuan QN, Li X, et al. Acta pharmacologica Sinica. 2026.
DOI: 10.1038/s41401-025-01635-2PubMed: 40847076
Editor's note
A cryo-EM structural study resolving how cagrilintide engages both amylin and calcitonin receptors via a shared binding mode. It clarifies the molecular basis of the drug's dual-receptor activity. Mechanistic rather than clinical, but directly focused on a tracked peptide.
Plain-language abstract
This structural biology study used cryo-EM to show how cagrilintide binds and activates amylin and calcitonin receptors.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026